Repurposing anticancer drugs for the management of COVID-19

Khalid El Bairi, Dario Trapani, Angelica Petrillo, Cécile Le Page, Hanaa Zbakh, Bruno Daniele, Rhizlane Belbaraka, Giuseppe Curigliano, Said Afqir

Research output: Contribution to journalReview articlepeer-review

Abstract

Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.

Original languageEnglish
Pages (from-to)40-61
Number of pages22
JournalEuropean Journal of Cancer
Volume141
DOIs
Publication statusPublished - Dec 2020

Keywords

  • Anticancer drugs
  • COVID-19
  • Repurposing
  • SARS-CoV-2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Repurposing anticancer drugs for the management of COVID-19'. Together they form a unique fingerprint.

Cite this